SB 706504

• UNSPSC Description:

  SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD)[1].

• Target Antigen:

  p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/sb-706504.html

• Solubility:

  10 mM in DMSO

• Smiles:

  N=C(NCCNC1=NC(C2=CC=C(F)C=C2C)=C(C=CC(N3C4=C(F)C=CC=C4F)=O)C3=N1)NC#N

• Molecular Weight:

  492.46

• References & Citations:

  [1]Lauren M. Kent, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504).

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  911110-38-8